CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2023 and reviewed recent business highlights.
“We continued to deliver strong commercial results in the third quarter, with the successful launch of AMVUTTRA contributing to 35% year-over-year growth in net product revenues,” said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. “While we were disappointed by the recent Complete Response Letter for ONPATTRO for the treatment of the cardiomyopathy of ATTR amyloidosis, we remain confident in the HELIOS-B Phase 3 study of vutrisiran, which is on track to deliver topline results in early 2024. We’re also excited about advancements across our broad pipeline of RNAi therapeutics, including recent positive topline results from the KARDIA-1 Phase 2 study of zilebesiran, as well as upcoming Phase 1 results for ALN-TTRsc04 and ALN-KHK by year-end. With this continued execution we remain on track to meet our Alnylam P5x25 goals of becoming a top-tier biotech company delivering sustained innovation and exceptional financial results.”
Third Quarter 2023 and Recent Significant Corporate Highlights
Commercial Performance
Total TTR: ONPATTRO® (patisiran) & AMVUTTRA® (vutrisiran)
- Achieved global net product revenues for ONPATTRO and AMVUTTRA for the third quarter of $82 million and $149 million, respectively, representing 35% total TTR reported year-over-year growth compared to Q3 2022.
- Attained over 3,790 hATTR amyloidosis patients with polyneuropathy worldwide on commercial treatment with ONPATTRO or AMVUTTRA as of September 30, 2023.
Total Ultra-Rare: GIVLAARI® (givosiran) & OXLUMO® (lumasiran)
- Achieved global net product revenues for GIVLAARI and OXLUMO for the third quarter of $54 million and $29 million, respectively, representing 33% total Ultra-Rare reported year-over-year growth compared to Q3 2022.
- Attained over 625 patients worldwide on commercial GIVLAARI treatment as of September 30, 2023.
- Attained over 375 patients worldwide on commercial OXLUMO treatment as of September 30, 2023.
Leqvio® (inclisiran)
- Leqvio launch in the U.S. and other markets is ongoing, with focus on patient on-boarding, removing access hurdles and enhancing medical education. In the U.S., Leqvio is covered at or near label for 76% of patients. More than 55% of Leqvio source of business in the U.S. is now through "Buy and Bill" acquisition mode. FDA expanded the label to include primary hyperlipidemia (patients at increased risk of ASCVD) and the removal of four adverse reactions from the safety section as well as Limitations of Use. In Q3 2023, Leqvio was approved in China and in Japan and is now approved in 93 countries.
R&D Highlights
Reported positive topline results from the KARDIA-1 Phase 2 dose-ranging study of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high cardiovascular risk.
Published results from Phase 1 study of zilebesiran in the New England Journal of Medicine.
Reported updated positive interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP in patients with early-onset Alzheimer’s disease at the 2023 Alzheimer’s Association International Conference and at the 16th Clinical Trials on Alzheimer’s Disease conference.
- Based on the achievement of specified clinical proof-of-principle criteria for the Phase 1 ALN-APP program, Alnylam received a $100 million milestone payment from Regeneron.
Presented new 24-month results from an interim analysis of the open-label extension period of the APOLLO-B Phase 3 study of patisiran in patients with the cardiomyopathy of transthyretin-mediated amyloidosis at the Heart Failure Society of America Annual Scientific Meeting 2023.
Published results from Phase 3 APOLLO-B study of patisiran in the New England Journal of Medicine.
Sanofi reported positive data for fitusiran, in development for the treatment of hemophilia A or B, with or without inhibitors, from the Phase 3 open-label extension study (ATLAS-OLE).
- Sanofi is currently in discussions with the FDA regarding filing in 2024.
Additional Business Updates
- Entered into a global strategic collaboration with Roche for the co-development and co-commercialization of zilebesiran.
- Recognized by Science magazine as a Top Employer for the fifth consecutive year.
Upcoming Events
Alnylam announces today that it will present a review of its RNAi platform and pipeline progress at a virtual R&D Day on December 13, 2023.
Alnylam announces today that results from the KARDIA-1 Phase 2 dose-ranging study of zilebesiran will be presented as a Late-Breaker at the American Heart Association Scientific Sessions 2023 on November 11, 2023, in Philadelphia, Pennsylvania.
In addition, in late 2023:
- Alnylam intends to report topline results from the Phase 1 study of ALN-TTRsc04.
- Alnylam intends to report topline results from the Phase 1 study of ALN-KHK.
-
Vir is conducting multiple trials evaluating the potential for ALN-HBV02 (VIR-2218) and VIR-3434 to achieve a functional cure for chronic hepatitis B. Phase 2 data readouts are on track for Q4 2023.
- Vir also announced that initial Phase 2 data readouts for the SOLSTICE trial evaluating ALN-HBV02 (VIR-2218) and VIR-3434 as monotherapy and in combination for the treatment of people living with chronic hepatitis delta, the most aggressive form of viral hepatitis, are expected in Q4 2023.
Financial Results for the Quarter Ended September 30, 2023
|
Three Months Ended
|
|||||
(in thousands, except per share amounts) |
2023 |
|
|
2022 |
|
|
Net product revenues |
$ |
313,153 |
|
$ |
232,267 |
|
Net revenue from collaborations |
$ |
427,472 |
|
$ |
29,297 |
|
Royalty revenue |
$ |
9,905 |
|
$ |
2,742 |
|
|
|
|
|
|||
GAAP Operating income (loss) |
$ |
213,867 |
|
$ |
(258,040 |
) |
Non-GAAP Operating income (loss) |
$ |
277,804 |
|
$ |
(129,922 |
) |
|
|
|
|
|||
GAAP Net income (loss) |
$ |
147,753 |
|
$ |
(405,920 |
) |
Non-GAAP Net income (loss) |
$ |
228,534 |
|
$ |
(193,366 |
) |
|
|
|
|
|||
GAAP net income (loss) per common share - basic |
$ |
1.18 |
|
$ |
(3.32 |
) |
Non-GAAP net income (loss) per common share - basic |
$ |
1.83 |
|
$ |
(1.58 |
) |
|
|
|
|
|||
GAAP net income (loss) per common share - diluted |
$ |
1.15 |
|
$ |
(3.32 |
) |
Non-GAAP net income (loss) per common share - diluted |
$ |
1.74 |
|
$ |
(1.58 |
) |
|
|
|
|
|||
* For an explanation of our use of non-GAAP financial measures refer to the "Use of Non-GAAP Financial Measures" section later in this press release and for a reconciliation of each non-GAAP financial measure to the most comparable GAAP measures, see the table at the end of this press release. |
||||||
Net Product Revenues
|
Three Months Ended
|
|
Year over Year %
|
||||||||
(in thousands, except percentages) |
|
2023 |
|
|
2022 |
|
As Reported |
|
At CER* |
||
ONPATTRO net product revenues |
$ |
81,589 |
|
$ |
144,950 |
|
(44 |
)% |
|
(46 |
)% |
AMVUTTRA net product revenues |
|
148,680 |
|
|
25,229 |
|
489 |
% |
|
488 |
% |
Total TTR net product revenues |
$ |
230,269 |
|
$ |
170,179 |
|
35 |
% |
|
34 |
% |
|
|
|
|
|
|
|
|
||||
GIVLAARI net product revenues |
|
54,148 |
|
|
45,659 |
|
19 |
% |
|
17 |
% |
OXLUMO net product revenues |
|
28,736 |
|
|
16,429 |
|
75 |
% |
|
69 |
% |
Total net product revenues |
$ |
313,153 |
|
$ |
232,267 |
|
35 |
% |
|
33 |
% |
|
|
|
|
|
|
|
|
||||
* CER = Constant Exchange Rate, representing growth calculated as if the exchange rates had remained unchanged from those used in the third quarter 2022. CER is a Non-GAAP measure. For an explanation of our use of non-GAAP financial measures refer to the "Use of Non-GAAP Financial Measures" section later in this press release and for a reconciliation of each non-GAAP financial measure to the most comparable GAAP measures, see the table at the end of this press release. |
|||||||||||
- Net product revenues increased 35% during the third quarter 2023, as compared to the prior year, and 33% at CER. The increase is primarily related to growth in our TTR product revenues driven by the launch of AMVUTTRA in the third quarter of 2022 as well as increased patients on GIVLAARI and OXLUMO therapies. The increase was offset by a decrease of demand for ONPATTRO due to patient switched to AMVUTTRA.
Net Revenues from Collaborations
- The increase in net revenues from collaborations, as compared to the prior year, is due to revenue related to our collaborations with Roche and Regeneron. During the quarter, we recognized $310 million of revenue from the upfront payment received from Roche and $65 million in connection with our Regeneron Collaboration. The $65 million of revenue is a cumulative adjustment from the $100 million milestone received for achieving certain criteria during early clinical development for our CNS program, ALN-APP.
Operating Expenses
|
Three Months Ended
|
|
2023 vs 2022 |
|||||||
(in thousands, except percentages) |
|
2023 |
|
|
|
2022 |
|
|
% Change* |
|
Cost of goods sold |
$ |
79,473 |
|
|
$ |
36,507 |
|
|
118 |
% |
Cost of goods sold as a percentage of net product revenues |
|
25.4 |
% |
|
|
15.7 |
% |
|
9.7 |
% |
|
|
|
|
|
|
|||||
Cost of collaborations |
$ |
4,836 |
|
|
$ |
4,609 |
|
|
5 |
% |
|
|
|
|
|
|
|||||
GAAP research and development expenses |
$ |
253,179 |
|
|
$ |
245,371 |
|
|
3 |
% |
Non-GAAP research and development expenses |
$ |
224,024 |
|
|
$ |
192,409 |
|
|
16 |
% |
|
|
|
|
|
|
|||||
GAAP selling, general and administrative expenses |
$ |
199,175 |
|
|
$ |
235,859 |
|
|
(16 |
)% |
Non-GAAP selling, general and administrative expenses |
$ |
164,393 |
|
|
$ |
160,703 |
|
|
2 |
% |
|
|
|
|
|
|
|||||
*For dollar values, we calculate the percentage of change during Q3 2023 compared to Q3 2022. For cost of goods sold as a percentage of net product revenues, we calculate the basis point change during Q3 2023 compared to Q3 2022. |
||||||||||
Cost of Goods Sold
- Cost of goods sold as a percent of net product revenues increased during the third quarter 2023, as compared to the prior year, primarily due to recording an impairment of ONPATTRO inventory that had been manufactured for future demand associated with the ATTR cardiomyopathy indication for patisiran for which we did not receive regulatory approval.
Research & Development (R&D) Expenses
- GAAP and non-GAAP R&D expenses increased during the third quarter 2023, as compared to the prior year, primarily due to increased costs related to clinical activities and increased headcount to support our R&D pipeline and an expense for the achievement of a certain clinical milestone payable to a partner. Increased GAAP R&D expenses were offset by decreased stock-based compensation expense related to the accounting for certain performance-based awards that vested in 2022.
Selling, General & Administrative (SG&A) Expenses
- GAAP SG&A expenses decreased during the third quarter 2023, as compared to the prior year, primarily due to decreased stock-based compensation expense related to the accounting for certain performance-based awards that vested in 2022. Non-GAAP SG&A expenses increased in the third quarter of 2023, compared to 2022, primarily due to increased headcount and other investments supporting our strategic growth including the global launch of AMVUTTRA.
Other Financial Highlights
- Cash, cash equivalents and marketable securities were $2.41 billion as of September 30, 2023 compared to $2.19 billion as of December 31, 2022 with the increase primarily related to the $310 million upfront payment received from Roche in connection with our partnership to co-develop and co-commercialize zilebesiran, offset by our operating loss year-to-date.
The adjustments to the non-GAAP measures provided in the financial results above and in the financial guidance below are described under “Use of Non-GAAP Financial Measures” later in this press release. A reconciliation of our GAAP to non-GAAP results presented in this release is included in the tables at the end of this press release.
2023 Financial Guidance
Full year 2023 financial guidance has been updated as follows:
|
|
Provided 2/23/20231 |
Updated 11/2/2023 |
Combined net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO1 |
|
$1,200 million - $1,285 million |
Unchanged |
Net Product Revenue Growth vs. 2022 at reported FX rates1 |
|
34% to 44% |
Unchanged |
Net Product Revenue Growth vs. 2022 at CER* |
|
34% to 44% |
Unchanged |
Net revenues from collaborations and royalties |
|
$100 million - $175 million |
$575 million - $625 million |
GAAP R&D and SG&A expenses |
|
$1,790 million - $1,885 million |
Unchanged |
Non-GAAP R&D and SG&A expenses2 |
|
$1,575 million - $1,650 million |
Unchanged |
|
|
|
|
1 Uses December 31, 2022 FX rates including: 1 EUR = 1.07 USD and 1 USD = 131 JPY |
|||
2 Excludes $215 - $235 million of stock-based compensation expense from estimated GAAP R&D and SG&A expenses |
|||
*CER = Constant Exchange Rate, representing growth calculated as if the exchange rates had remained unchanged from those used in the twelve months ended December 31, 2022. CER is a Non-GAAP measure. |
|||
Use of Non-GAAP Financial Measures
This press release contains non-GAAP financial measures, including expenses adjusted to exclude certain non-cash expenses and certain losses outside the ordinary course of the Company’s business. These measures are not in accordance with, or an alternative to, GAAP, and may be different from non-GAAP financial measures used by other companies.
The non-GAAP financial measures we present include Non-GAAP Operating income (loss), Non-GAAP Net income (loss), Non-GAAP Net income (loss) per common share - basic, Non-GAAP Net income (loss) per common share - diluted and Non-GAAP R&D and SG&A expenses. The items included in GAAP presentations but excluded for purposes of determining non-GAAP financial measures for the periods presented in this press release are stock-based compensation expenses and realized and unrealized losses on marketable equity securities. The Company has excluded the impact of stock-based compensation expense, which may fluctuate from period to period based on factors including the variability associated with performance-based grants for stock options and restricted stock units and changes in the Company’s stock price, which impacts the fair value of these awards. The Company has excluded the impact of the realized and unrealized losses on marketable equity securities because the Company does not believe these adjustments accurately reflect the performance of the Company’s ongoing operations for the period in which such gains or losses are reported, as their sole purpose is to adjust amounts on the balance sheet.
Percentage changes in revenue growth at CER, also a non-GAAP financial measure, are presented excluding the impact of changes in foreign currency exchange rates for investors to understand the underlying business performance. The current period’s foreign currency revenue values are converted into U.S. dollars using the average exchange rates from the prior period.
The Company believes the presentation of non-GAAP financial measures provides useful information to management and investors regarding the Company’s financial condition and results of operations. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company’s ongoing operating performance and are better able to compare the Company’s performance between periods. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation between historical GAAP and non-GAAP measures presented in this release is provided later in this press release.
Conference Call Information
Management will provide an update on the Company and discuss third quarter 2023 results as well as expectations for the future via conference call on Thursday, November 2, 2023 at 8:30 am ET. To access the call, please register online at https://register.vevent.com/register/BI29582eb5fd274b758554baecef8f03fa. Participants are requested to register at a minimum 15 minutes before the start of the call. A replay of the call will be available two hours after the call and archived on the same web page for six months.
A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event.
About ONPATTRO® (patisiran)
ONPATTRO is an RNAi therapeutic that is approved in the United States and Canada for the treatment of the polyneuropathy of hATTR amyloidosis in adults. ONPATTRO is also approved in the European Union, Switzerland and Brazil for the treatment of hATTR amyloidosis in adults with Stage 1 or Stage 2 polyneuropathy, and in Japan for the treatment of hATTR amyloidosis with polyneuropathy. ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin (TTR). It is designed to target and silence TTR messenger RNA, thereby reducing the production of TTR protein before it is made. Reducing the pathogenic protein leads to a reduction in amyloid deposits in tissues. For more information about ONPATTRO, including full Prescribing Information, visit ONPATTRO.com.
About AMVUTTRA® (vutrisiran)
AMVUTTRA® (vutrisiran) is an RNAi therapeutic approved in the United States for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. It is a double-stranded small interfering RNA (siRNA) that targets mutant and wild-type transthyretin (TTR) messenger RNA (mRNA). Using Alnylam’s Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate delivery platform, AMVUTTRA is designed for increased potency and high metabolic stability to allow for subcutaneous injection once every three months (quarterly). Results from the pivotal HELIOS-A Phase 3 study demonstrate AMVUTTRA rapidly reduces serum TTR levels, has the potential to reverse neuropathy impairment relative to baseline and improves other key measures of disease burden relative to external placebo in patients with the polyneuropathy of hATTR amyloidosis. For more information about AMVUTTRA, including the full U.S. Prescribing Information, visit AMVUTTRA.com.
About GIVLAARI® (givosiran)
GIVLAARI (givosiran) is an RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) approved in the United States and Brazil for the treatment of adults with acute hepatic porphyria (AHP). GIVLAARI is also approved in the European Union for the treatment of AHP in adults and adolescents aged 12 years and older. In the pivotal study, givosiran was shown to significantly reduce the rate of porphyria attacks that required hospitalizations, urgent healthcare visits or intravenous hemin administration at home compared to placebo. GIVLAARI is Alnylam’s first commercially available therapeutic based on its Enhanced Stabilization Chemistry ESC-GalNAc conjugate technology to increase potency and durability. GIVLAARI is administered via subcutaneous injection once monthly at a dose based on actual body weight and should be administered by a healthcare professional. GIVLAARI works by specifically reducing elevated levels of ALAS1 messenger RNA (mRNA), leading to reduction of toxins associated with attacks and other disease manifestations of AHP. For more information about GIVLAARI, including the full U.S. Prescribing Information, visit GIVLAARI.com.
About OXLUMO® (lumasiran)
OXLUMO (lumasiran) is an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1). HAO1 encodes glycolate oxidase (GO). Thus, by silencing HAO1 and depleting the GO enzyme, OXLUMO inhibits production of oxalate – the metabolite that directly contributes to the pathophysiology of PH1. OXLUMO utilizes Alnylam’s Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate technology, which enables subcutaneous dosing with increased potency and durability and a wide therapeutic index. OXLUMO has received regulatory approvals from the U.S. Food and Drug Administration (FDA) for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients and from the European Medicines Agency (EMA) for the treatment of PH1 in all age groups. In the pivotal ILLUMINATE-A study, OXLUMO was shown to significantly reduce levels of urinary oxalate relative to placebo, with the majority of patients reaching normal or near-normal levels. In the ILLUMINATE-B pediatric Phase 3 study, OXLUMO demonstrated an efficacy and safety profile consistent to that observed in ILLUMINATE-A. In the ILLUMINATE-C study, OXLUMO resulted in substantial reductions in plasma oxalate in patients with advanced PH1. Across all three studies, injection site reactions (ISRs) were the most common drug-related adverse reaction. OXLUMO is administered via subcutaneous injection once monthly for three months, then once quarterly beginning one month after the last loading dose at a dose based on actual body weight. For patients who weigh less than 10 kg, ongoing dosing remains monthly. OXLUMO should be administered by a healthcare professional. For more information about OXLUMO, including the full U.S. Prescribing Information, visit OXLUMO.com.
About LNP Technology
Alnylam has licenses to Arbutus Biopharma LNP intellectual property for use in RNAi therapeutic products using LNP technology.
About RNAi
RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as “a major scientific breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran) and Leqvio® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on X (formerly Twitter) at @Alnylam, or on LinkedIn, Facebook on Instagram.
Alnylam Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam’s expectations, beliefs, goals, plans or prospects including, without limitation, expectations regarding Alnylam’s aspiration to become a leading biotech company and the planned achievement of its “Alnylam P5x25” strategy, the potential for Alnylam to identify new potential drug development candidates and advance its research and development programs, Alnylam’s ability to obtain approval for new commercial products or additional indications for its existing products, and Alnylam’s projected commercial and financial performance, should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation: the direct or indirect impact of the COVID-19 global pandemic or any future pandemic on Alnylam’s business, results of operations and financial condition; Alnylam’s ability to successfully execute on its “Alnylam P5x25” strategy; Alnylam’s ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam’s product candidates, including vutrisiran; actions or advice of regulatory agencies and Alnylam’s ability to obtain and maintain regulatory approval for its product candidates, including vutrisiran, as well as favorable pricing and reimbursement; successfully launching, marketing and selling Alnylam’s approved products globally; delays, interruptions or failures in the manufacture and supply of Alnylam’s product candidates or its marketed products; delays or interruptions in the supply of resources needed to advance Alnylam’s research and development programs, including as may arise from recent disruptions in the supply of non-human primates; obtaining, maintaining and protecting intellectual property; Alnylam’s ability to successfully expand the indication AMVUTTRA in the future; Alnylam’s ability to manage its growth and operating expenses through disciplined investment in operations and its ability to achieve a self-sustainable financial profile in the future without the need for future equity financing; Alnylam’s ability to maintain strategic business collaborations; Alnylam’s dependence on third parties for the development and commercialization of certain products, including Roche, Novartis, Sanofi, Regeneron and Vir; the outcome of litigation; the risks of future government investigations; and unexpected expenditures; as well as those risks more fully discussed in the “Risk Factors” filed with Alnylam's 2022 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam’s subsequent Quarterly Reports on Form 10-Q and in its other SEC filings. In addition, any forward-looking statements represent Alnylam’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.
This release discusses investigational RNAi therapeutics and uses of previously approved RNAi therapeutics in development and is not intended to convey conclusions about efficacy or safety as to those investigational therapeutics or uses. Patisiran has not been approved by any regulatory agency for the treatment of ATTR amyloidosis with cardiomyopathy. No conclusions can or should be drawn regarding its safety or effectiveness in treating cardiomyopathy in this population. There is no guarantee that any investigational therapeutics or expanded uses of commercial products will successfully complete clinical development or gain health authority approval.
ALNYLAM PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share amounts) (Unaudited) |
|||||||||||||||
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
September 30,
|
|
September 30,
|
|
September 30,
|
|
September 30,
|
||||||||
Statements of Operations |
|
|
|
|
|
|
|
||||||||
Revenues: |
|
|
|
|
|
|
|
||||||||
Net product revenues |
$ |
313,153 |
|
|
$ |
232,267 |
|
|
$ |
895,186 |
|
|
$ |
632,654 |
|
Net revenues from collaborations |
|
427,472 |
|
|
|
29,297 |
|
|
|
469,778 |
|
|
|
64,267 |
|
Royalty revenue |
|
9,905 |
|
|
|
2,742 |
|
|
|
23,610 |
|
|
|
5,462 |
|
Total revenues |
|
750,530 |
|
|
|
264,306 |
|
|
|
1,388,574 |
|
|
|
702,383 |
|
|
|
|
|
|
|
|
|
||||||||
Operating costs and expenses: |
|
|
|
|
|
|
|
||||||||
Cost of goods sold |
|
79,473 |
|
|
|
36,507 |
|
|
|
196,241 |
|
|
|
94,002 |
|
Cost of collaborations and royalties |
|
4,836 |
|
|
|
4,609 |
|
|
|
28,307 |
|
|
|
23,549 |
|
Research and development |
|
253,179 |
|
|
|
245,371 |
|
|
|
732,274 |
|
|
|
620,976 |
|
Selling, general and administrative |
|
199,175 |
|
|
|
235,859 |
|
|
|
597,523 |
|
|
|
560,314 |
|
Total operating costs and expenses |
|
536,663 |
|
|
|
522,346 |
|
|
|
1,554,345 |
|
|
|
1,298,841 |
|
Income (loss) from operations |
|
213,867 |
|
|
|
(258,040 |
) |
|
|
(165,771 |
) |
|
|
(596,458 |
) |
Other (expense) income: |
|
|
|
|
|
|
|
||||||||
Interest expense |
|
(30,893 |
) |
|
|
(41,084 |
) |
|
|
(89,883 |
) |
|
|
(126,055 |
) |
Interest income |
|
25,425 |
|
|
|
7,820 |
|
|
|
65,155 |
|
|
|
10,731 |
|
Other expense, net |
|
(57,658 |
) |
|
|
(38,053 |
) |
|
|
(105,331 |
) |
|
|
(131,604 |
) |
Loss on the extinguishment of debt |
|
— |
|
|
|
(76,586 |
) |
|
|
— |
|
|
|
(76,586 |
) |
Total other expense, net |
|
(63,126 |
) |
|
|
(147,903 |
) |
|
|
(130,059 |
) |
|
|
(323,514 |
) |
Income (loss) before income taxes |
|
150,741 |
|
|
|
(405,943 |
) |
|
|
(295,830 |
) |
|
|
(919,972 |
) |
(Provision for) benefit from income taxes |
|
(2,988 |
) |
|
|
23 |
|
|
|
(6,542 |
) |
|
|
(3,691 |
) |
Net income (loss) |
$ |
147,753 |
|
|
$ |
(405,920 |
) |
|
$ |
(302,372 |
) |
|
$ |
(923,663 |
) |
|
|
|
|
|
|
|
|
||||||||
Net income (loss) per common share - basic |
$ |
1.18 |
|
|
$ |
(3.32 |
) |
|
$ |
(2.43 |
) |
|
$ |
(7.62 |
) |
Net income (loss) per common share - diluted |
$ |
1.15 |
|
|
$ |
(3.32 |
) |
|
$ |
(2.43 |
) |
|
$ |
(7.62 |
) |
|
|
|
|
|
|
|
|
||||||||
Weighted-average common shares- basic |
|
125,220 |
|
|
|
122,166 |
|
|
|
124,667 |
|
|
|
121,158 |
|
Weighted-average common shares- diluted |
|
131,337 |
|
|
|
122,166 |
|
|
|
124,667 |
|
|
|
121,158 |
|
ALNYLAM PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except per share amounts) (Unaudited) |
|||||||
September 30, 2023 |
|
December 31, 2022 |
|||||
ASSETS |
|
|
|
||||
Current assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
1,033,024 |
|
|
$ |
866,394 |
|
Marketable debt securities |
|
1,362,843 |
|
|
|
1,297,890 |
|
Marketable equity securities |
|
10,411 |
|
|
|
28,122 |
|
Accounts receivable, net |
|
325,445 |
|
|
|
237,963 |
|
Inventory |
|
95,771 |
|
|
|
128,962 |
|
Prepaid expenses and other current assets |
|
157,958 |
|
|
|
132,916 |
|
Total current assets |
|
2,985,452 |
|
|
|
2,692,247 |
|
Property, plant and equipment, net |
|
525,591 |
|
|
|
523,494 |
|
Operating lease right-of-use assets |
|
203,485 |
|
|
|
215,136 |
|
Restricted investments |
|
49,390 |
|
|
|
49,390 |
|
Other assets |
|
75,155 |
|
|
|
66,092 |
|
Total assets |
$ |
3,839,073 |
|
|
$ |
3,546,359 |
|
LIABILITIES AND STOCKHOLDERS’ DEFICIT |
|
|
|
||||
Current liabilities: |
|
|
|
||||
Accounts payable |
$ |
73,840 |
|
|
$ |
98,094 |
|
Accrued expenses |
|
713,094 |
|
|
|
545,460 |
|
Operating lease liability |
|
41,516 |
|
|
|
41,967 |
|
Deferred revenue |
|
77,140 |
|
|
|
42,105 |
|
Liability related to the sale of future royalties |
|
44,195 |
|
|
|
40,289 |
|
Total current liabilities |
|
949,785 |
|
|
|
767,915 |
|
Operating lease liability, net of current portion |
|
247,711 |
|
|
|
261,339 |
|
Deferred revenue, net of current portion |
|
196,086 |
|
|
|
193,791 |
|
Convertible debt |
|
1,019,809 |
|
|
|
1,016,942 |
|
Liability related to the sale of future royalties, net of current portion |
|
1,310,814 |
|
|
|
1,252,015 |
|
Other liabilities |
|
280,734 |
|
|
|
212,580 |
|
Total liabilities |
|
4,004,939 |
|
|
|
3,704,582 |
|
Commitments and contingencies (Note 13) |
|
|
|
||||
Stockholders’ deficit: |
|
|
|
||||
Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of September 30, 2023 and December 31, 2022 |
|
— |
|
|
|
— |
|
Common stock, $0.01 par value per share, 250,000 shares authorized; 125,454 shares issued and outstanding as of September 30, 2023; 123,925 shares issued and outstanding as of December 31, 2022 |
|
1,255 |
|
|
|
1,240 |
|
Additional paid-in capital |
|
6,736,939 |
|
|
|
6,454,540 |
|
Accumulated other comprehensive loss |
|
(32,339 |
) |
|
|
(44,654 |
) |
Accumulated deficit |
|
(6,871,721 |
) |
|
|
(6,569,349 |
) |
Total stockholders’ deficit |
|
(165,866 |
) |
|
|
(158,223 |
) |
Total liabilities and stockholders’ deficit |
$ |
3,839,073 |
|
|
$ |
3,546,359 |
|
This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alnylam’s Annual Report on Form 10-K which includes the audited financial statements for the year ended December 31, 2022.
ALNYLAM PHARMACEUTICALS, INC. RECONCILIATION OF SELECTED GAAP MEASURES TO NON-GAAP MEASURES (In thousands, except per share amounts) (Unaudited) |
|||||||||||||||
|
Three Months Ended |
|
Nine Months Ended |
||||||||||||
|
September 30,
|
|
September 30,
|
|
September 30,
|
|
September 30,
|
||||||||
Reconciliation of GAAP to Non-GAAP research and development: |
|
|
|
|
|
|
|
||||||||
GAAP research and development |
$ |
253,179 |
|
|
$ |
245,371 |
|
|
$ |
732,274 |
|
|
$ |
620,976 |
|
Less: Stock-based compensation expenses |
|
(29,155 |
) |
|
|
(52,962 |
) |
|
|
(78,188 |
) |
|
|
(75,217 |
) |
Non-GAAP research and development |
$ |
224,024 |
|
|
$ |
192,409 |
|
|
$ |
654,086 |
|
|
$ |
545,759 |
|
|
|
|
|
|
|
|
|
||||||||
Reconciliation of GAAP to Non-GAAP selling, general and administrative: |
|
|
|
|
|
|
|||||||||
GAAP selling, general and administrative |
$ |
199,175 |
|
|
$ |
235,859 |
|
|
$ |
597,523 |
|
|
$ |
560,314 |
|
Less: Stock-based compensation expenses |
|
(34,782 |
) |
|
|
(75,156 |
) |
|
|
(101,498 |
) |
|
|
(112,665 |
) |
Non-GAAP selling, general and administrative |
$ |
164,393 |
|
|
$ |
160,703 |
|
|
$ |
496,025 |
|
|
$ |
447,649 |
|
|
|
|
|
|
|
|
|
||||||||
Reconciliation of GAAP to Non-GAAP operating income (loss): |
|
|
|
|
|
|
|
||||||||
GAAP operating income (loss) |
$ |
213,867 |
|
|
$ |
(258,040 |
) |
|
$ |
(165,771 |
) |
|
$ |
(596,458 |
) |
Add: Stock-based compensation expenses |
|
63,937 |
|
|
|
128,118 |
|
|
|
179,686 |
|
|
|
187,882 |
|
Non-GAAP operating income (loss) |
$ |
277,804 |
|
|
$ |
(129,922 |
) |
|
$ |
13,915 |
|
|
$ |
(408,576 |
) |
|
|
|
|
|
|
|
|
||||||||
Reconciliation of GAAP to Non-GAAP net income (loss): |
|
|
|
|
|
|
|
||||||||
GAAP net income (loss) |
$ |
147,753 |
|
|
$ |
(405,920 |
) |
|
$ |
(302,372 |
) |
|
$ |
(923,663 |
) |
Add: Stock-based compensation expenses |
|
63,937 |
|
|
|
128,118 |
|
|
|
179,686 |
|
|
|
187,882 |
|
Add: Realized and unrealized loss on marketable equity securities |
|
16,844 |
|
|
|
7,850 |
|
|
|
17,711 |
|
|
|
40,108 |
|
Add: Loss on the extinguishment of debt |
|
— |
|
|
|
76,586 |
|
|
|
— |
|
|
|
76,586 |
|
Non-GAAP net income (loss) |
$ |
228,534 |
|
|
$ |
(193,366 |
) |
|
$ |
(104,975 |
) |
|
$ |
(619,087 |
) |
|
|
|
|
|
|
|
|
||||||||
Reconciliation of GAAP to Non-GAAP net income (loss) per common share- basic: |
|
|
|
|
|||||||||||
GAAP net income (loss) per common share - basic |
$ |
1.18 |
|
|
$ |
(3.32 |
) |
|
$ |
(2.43 |
) |
|
$ |
(7.62 |
) |
Add: Stock-based compensation expenses |
|
0.51 |
|
|
|
1.05 |
|
|
|
1.44 |
|
|
|
1.55 |
|
Add: Realized and unrealized loss on marketable equity securities |
|
0.13 |
|
|
|
0.06 |
|
|
|
0.14 |
|
|
|
0.33 |
|
Add: Loss on the extinguishment of debt |
|
— |
|
|
|
0.63 |
|
|
|
— |
|
|
|
0.63 |
|
Non-GAAP net income (loss) per common share - basic |
$ |
1.83 |
|
|
$ |
(1.58 |
) |
|
$ |
(0.84 |
) |
|
$ |
(5.11 |
) |
|
|
|
|
|
|
|
|
||||||||
Reconciliation of GAAP to Non-GAAP net income (loss) per common share- diluted: |
|
|
|
|
|||||||||||
GAAP net income (loss) per common share - diluted |
$ |
1.15 |
|
|
$ |
(3.32 |
) |
|
$ |
(2.43 |
) |
|
$ |
(7.62 |
) |
Add: Stock-based compensation expenses |
|
0.49 |
|
|
|
1.05 |
|
|
|
1.44 |
|
|
|
1.55 |
|
Add: Realized and unrealized loss on marketable equity securities |
|
0.13 |
|
|
|
0.06 |
|
|
|
0.14 |
|
|
|
0.33 |
|
Add: Loss on the extinguishment of debt |
|
— |
|
|
|
0.63 |
|
|
|
— |
|
|
|
0.63 |
|
Non-GAAP net income (loss) per common share - diluted |
$ |
1.74 |
|
|
$ |
(1.58 |
) |
|
$ |
(0.84 |
) |
|
$ |
(5.11 |
) |
Please note that the figures presented above may not sum exactly due to rounding |
|||||||||||||||
ALNYLAM PHARMACEUTICALS, INC. RECONCILIATION OF GAAP TO NON-GAAP PRODUCT REVENUE GROWTH AT CONSTANT CURRENCY (Unaudited) |
|||||
|
September 30, 2023 |
||||
|
Three Months Ended |
|
Nine Months Ended |
||
ONPATTRO net product revenue growth, as reported |
(44 |
)% |
|
(37 |
)% |
Add: Impact of foreign currency translation |
(2 |
) |
|
— |
|
ONPATTRO net product revenue growth at constant currency |
(46 |
)% |
|
(37 |
)% |
|
|
|
|
||
AMVUTTRA net product revenue growth, as reported |
489 |
% |
|
1416 |
% |
Add: Impact of foreign currency translation |
(1 |
) |
|
18 |
|
AMVUTTRA net product revenue growth at constant currency |
488 |
% |
|
1434 |
% |
|
|
|
|
||
Total TTR net product revenue growth, as reported |
35 |
% |
|
43 |
% |
Add: Impact of foreign currency translation |
(1 |
) |
|
1 |
|
Total TTR net product revenue growth at constant currency |
34 |
% |
|
44 |
% |
|
|
|
|
||
GIVLAARI net product revenue growth, as reported |
19 |
% |
|
27 |
% |
Add: Impact of foreign currency translation |
(2 |
) |
|
— |
|
GIVLAARI net product revenue growth at constant currency |
17 |
% |
|
27 |
% |
|
|
|
|
||
OXLUMO net product revenue growth, as reported |
75 |
% |
|
68 |
% |
Add: Impact of foreign currency translation |
(6 |
) |
|
(1 |
) |
OXLUMO net product revenue growth at constant currency |
69 |
% |
|
67 |
% |
|
|
|
|
||
Total net product revenue growth, as reported |
35 |
% |
|
41 |
% |
Add: Impact of foreign currency translation |
(2 |
) |
|
1 |
|
Total net product revenue growth at constant currency |
33 |
% |
|
42 |
% |
